Peptide Based Infection Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022

Published on : Aug-2017 | List of Tables : 140 | List of Figures : 42 | No. of Pages : 170 | Report Code : FACT188MR | Format : ppt pdf Excel Word

There is a need to develop novel therapeutic agents in order to fight infections. Peptide therapeutics are used to fight infectious diseases. The global peptide based infection therapeutics market is expected to grow in the future owing to factors such as cost effectiveness of peptides, higher efficacy of peptides in managing various disease indications and infections, and can be easily synthesized owing to smaller size. Moreover, few economic factors such as government policies for startup companies, increasing foreign direct investment, as well as higher investment in healthcare are also driving the global peptide based infection therapeutics market. The rising prevalence of infectious diseases has resulted in providing an impetus to the use of peptides therapeutics to treat infections. Along with this, emerging biotech and pharmaceutical companies, strong and advanced pipelines and patent expiries are few other aspects impacting the growth of the global peptide based infection therapeutics market positively. To support this, the advancements in technology and increased research and development and the rising investments in these fields have led to the growing importance of global peptide based infection therapeutics market. North America is expected to show higher attractiveness in this market.

Peptide therapeutics are stable, safe, tolerable, possess selective nature, and effective. They are used in the treatment of infections owing to their broad spectrum of activities and mechanisms. They protect the host from pathogenic microbes and are also referred to as host defense peptides owing to their functionality in protecting the immunity system and fighting against infections.

According to Fact.MR’s research report on the global peptide based infection therapeutics market, the market is anticipated to show a robust growth rate during the forecasted period of 2017-2022 and expected to reflect a value a bit less than US$ 1.5 Bn.

Market Taxonomy

Drug

Distribution Channel

Telaprevir

Hospital Pharmacies

Boceprevir

Retail Pharmacies

 

Online Pharmacies

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

Domination of North America in the Peptide Based Infection Therapeutics Market

With respect to the global peptide based infection therapeutics market, according to the market observation in 2016 and 2017, the region of North America is expected to dominate the global market in terms of higher market share by revenue and is poised to grow at a higher growth rate to register a CAGR during the period of forecast. North America shows higher market attractiveness; this growth mainly attributed to the higher investment in the healthcare industry along with rapid technological developments. Latin America and Middle East and Africa (MEA) regions show relatively slow growth rate as compared to North America region and a fairly less market share and this trend is anticipated to continue during the period of forecast, 2017 to 2022.

APEJ to Show Tremendous Activity as Compared to Europe

The Asia-Pacific excluding Japan (APEJ) region is expected to show a rapid growth rate and is expected to register a CAGR of 8.7% during the period of forecast. The main reasons for this kind of growth is the strict government regulations for the upcoming players, higher number of pharmaceutical companies, increased foreign direct investment and development of technologies. Moreover, the government encourages to increase the investment in the healthcare industry to discover and invent new methods and technologies to better the health of the patients and enhance patient outcome. Following Asia-Pacific excluding Japan (APEJ) region, Europe regions also shows good growth rate in the global peptide based infection therapeutics market.

Telaprivir Set to Dominate the Global Market

The telaprivir segment by drug type is expected to dominate the market in terms of market share by revenue, as of 2016 and expected to show a similar trend in 2017 as well. However, the boceprevir segment grows at a higher rate during the period of forecast as compared to telaprivir yet experiences less market share by revenue comparatively. However, with the higher rate of growth throughout the forecast period, it could be a case that the domination title might shift from telaprivir to boceprivir.

Online Pharmacies to Show Robust Growth Rate, Would Just be an Understatement

The online pharmacies segment by distribution channel is anticipated to show exponential growth rate to register a CAGR of 9.2% throughout the period of forecast, 2017 to 2022. This growth can be attributed towards the increasing awareness of the online concept, its effectiveness, reliability and convenience. However, this segment, still being in its nascent phase, has less market share as compared to other segments in the distribution channel category. The online segment is also expected to experience a higher gain in the BPS by the end of 2022. The online pharmacies segment reflects the highest growth in the North America region rate as compared to other regions during the period of forecast.

Hospital vs. Retail Pharmacies, a Touch Call to Make

Hospital pharmacies segment enjoys the highest market share by revenue thereby dominating the global market, as per market observations in 2016 and 2017. This trend could keep up with the growth rate that it reflects. However, the retail pharmacies segment shows a higher growth rate, yet less market share. It is anticipated to reflect a higher growth rate and poised to register a CAGR of 7.9% during the period of forecast of 2017 to 2022. The regions favoring the growth of the hospital pharmacy segment is APEJ followed by Europe. APEJ is also favorable for retail pharmacies segment, in fact the growth of retail pharmacies in this region is the highest as compared to other regions, as per anticipations. Asia-Pacific excluding Japan expected to stay strong with respect to all the segments by distribution channel, except for the online pharmacies segment which finds better shelter in North America region.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of the global peptide based infection therapeutics market through 2022, which include Vertex Pharmaceuticals Incorporated, Merck & Co., Inc. and Parchem Fine & Specialty Chemicals.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Peptide therapeutics are used to treat infectious diseases. The global peptide based infection therapeutics market is impacted by aspects which link to the advantages of peptides in treating diseases, the government regulations to better the healthcare industry, the increasing foreign direct investments, the rising investments in healthcare, the increasing bio-pharma companies, etc. This Fact.MR report analyzes the expansion of global peptide based infection therapeutics market till date, and provides key insights on the growth of the market during the forecast period, 2017-2022.

Scope

The scope of Fact.MR’s report is to analyze the global peptide based infection therapeutics market for the forecast period 2017-2022 and provide readers an unbiased and accurate analysis. Medical device manufacturers, research institutes, and raw material suppliers in the global peptide based infection therapeutics market can benefit from the analysis offered in this report. This report offers a comprehensive analysis, which can be of interest to leading trade magazines and medical journals pertaining to peptide based infection therapeutics.

Summary

The report commences with a brief information of the global peptide based infection therapeutics market. This executive summary sets the tone for the rest of the report, providing users the scope of the report. The executive summary includes important facts and statistics on the global peptide based infection therapeutics market.

Overview

The next section offers an overview of the global peptide based infection therapeutics market. This comprises an introduction to the market, along with a standard definition of the product – peptide based infection therapeutics. In this section, market value and year-over-year growth is offered to the readers. Year-over-year growth provides readers with a broader view of growth patterns over the forecast period.

The report’s succeeding section focuses on drivers, restraints and key trends from macroeconomic, demand, and supply perspectives. Impact analysis of weighted average model-based growth drivers is contained in the report for better provision of decision-making insights to clients.

In order to offer readers with up-to-date information about the latest advancements in the global peptide based infection therapeutics market, the report provides updates about market opportunities, which can benefit leading manufacturers of peptide based infection therapeutics. With continuous evolution of the healthcare sector, keeping a record of latest developments and trends is fundamental for peptide based infection therapeutics manufacturers to formulate key business strategies. Detailed insights about raw material sourcing, supply chain, regulatory approvals, pricing analysis, list of distributors, and cost structure are provided in this section.

The Fact.MR report provides segment-wise analysis and forecast for covering the wide scope of global peptide based infection therapeutics market. Drug type, distribution channel and region are key segments that define the growth of the global market for peptide based infection therapeutics. In this segmentation analysis, a detailed country-wise forecast across all key market parameters is also included.

The report’s last section comprises of the global peptide based infection therapeutics market competitive landscape, to provide readers with the dashboard view of company analysis and market players. This competitive intelligence is based on the providers’ categories across value chain, and their presence in the global peptide based infection therapeutics market.

Research Methodology

Fact.MR is committed to offer unbiased and independent market research solutions to its clients. Each market report of Fact.MR is compiled after months of exhaustive research. We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,

  • Primary research
  • Secondary research
  • Trade research
  • Focused interviews
  • Social media analysis

1. Global Peptide Based Infection Therapeutics Market - Executive Summary

2. Global Peptide Based Infection Therapeutics Market Overview
2.1. Introduction
       2.1.1. Global Peptide Based Infection Therapeutics Market Taxonomy
       2.1.2. Global Peptide Based Infection Therapeutics Market Definition
2.2. Global Peptide Based Infection Therapeutics Market Size (US$ Mn) and Forecast, 2012-2022
       2.2.1. Global Peptide Based Infection Therapeutics Market Y-o-Y Growth
2.3. Global Peptide Based Infection Therapeutics Market Dynamics
2.4. Regulations
2.5. Supply Chain
2.6. Cost Structure
2.7. Average Pricing Analysis 
2.8. Epidemiology
2.9. Key Participants Market Presence (Intensity Map) By Region

3. Global Peptide Based Infection Therapeutics Market Analysis and Forecast By Drug 
3.1. Global Peptide Based Infection Therapeutics Market Size and Forecast By Drug, 2012-2022
       3.1.1. Telaprevir Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
                3.1.1.1. Revenue (US$ Mn) Comparison, By Region
                3.1.1.2. Market Share Comparison, By Region
                3.1.1.3. Y-o-Y growth Comparison, By Region
       3.1.2. Boceprevir Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region
                3.1.2.2. Market Share Comparison, By Region
                3.1.2.3. Y-o-Y growth Comparison, By Region

4. Global Peptide Based Infection Therapeutics Market Analysis and Forecast By Distribution Channel 
4.1. Global Peptide Based Infection Therapeutics Market Size and Forecast By Distribution Channel, 2012-2022
       4.1.1. Hospital Pharmacies Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
                4.1.1.1. Revenue (US$ Mn) Comparison, By Region
                4.1.1.2. Market Share Comparison, By Region
                4.1.1.3. Y-o-Y growth Comparison, By Region
       4.1.2. Retail Pharmacies Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
                4.1.2.1. Revenue (US$ Mn) Comparison, By Region
                4.1.2.2. Market Share Comparison, By Region
                4.1.2.3. Y-o-Y growth Comparison, By Region
       4.1.3. Online Pharmacies Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
                4.1.3.1. Revenue (US$ Mn) Comparison, By Region
                4.1.3.2. Market Share Comparison, By Region
                4.1.3.3. Y-o-Y growth Comparison, By Region

5. Global Peptide Based Infection Therapeutics Market Analysis and Forecast By Region
5.1. Global Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       5.1.1. North America Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
                5.1.1.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.2. Latin America Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
                5.1.2.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.3. Europe Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
                5.1.3.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.4. Japan Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
                5.1.4.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.5. APEJ Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
                5.1.5.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.6. MEA Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
                5.1.6.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

6. North America Peptide Based Infection Therapeutics Market Analysis and Forecast, By Country, 2012-2022
6.1. US Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       6.1.1. Revenue (US$ Mn) Comparison, By Drug 
       6.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
6.2. Canada Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       6.2.1. Revenue (US$ Mn) Comparison, By Drug 
       6.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

7. Latin America Peptide Based Infection Therapeutics Market Analysis and Forecast, By Country, 2012-2022
7.1. Brazil Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       7.1.1. Revenue (US$ Mn) Comparison, By Drug 
       7.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
7.2. Mexico Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       7.2.1. Revenue (US$ Mn) Comparison, By Drug 
       7.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
7.3. Argentina Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       7.3.1. Revenue (US$ Mn) Comparison, By Drug 
       7.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

8. Europe Peptide Based Infection Therapeutics Market Analysis and Forecast, By Country, 2012-2022
8.1. Germany Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       8.1.1. Revenue (US$ Mn) Comparison, By Drug 
       8.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.2. UK Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       8.2.1. Revenue (US$ Mn) Comparison, By Drug 
       8.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.3. France Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       8.3.1. Revenue (US$ Mn) Comparison, By Drug 
       8.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.4. Spain Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       8.4.1. Revenue (US$ Mn) Comparison, By Drug 
       8.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.5. Italy Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       8.5.1. Revenue (US$ Mn) Comparison, By Drug 
       8.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.6. Nordic Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       8.6.1. Revenue (US$ Mn) Comparison, By Drug 
       8.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

9. Japan Peptide Based Infection Therapeutics Market Analysis and Forecast, By Country, 2012-2022
9.1. Japan  Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       9.1.1. Revenue (US$ Mn) Comparison, By Drug 
       9.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

10. APEJ Peptide Based Infection Therapeutics Market Analysis and Forecast, By Country, 2012-2022
10.1. China Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       10.1.1. Revenue (US$ Mn) Comparison, By Drug 
       10.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.2. India Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       10.2.1. Revenue (US$ Mn) Comparison, By Drug 
       10.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.3. Malaysia Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       10.3.1. Revenue (US$ Mn) Comparison, By Drug 
       10.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.4. Thailand Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       10.4.1. Revenue (US$ Mn) Comparison, By Drug 
       10.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.5. Singapore Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       10.5.1. Revenue (US$ Mn) Comparison, By Drug 
       10.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.6. Australia Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       10.6.1. Revenue (US$ Mn) Comparison, By Drug 
       10.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

11. MEA Peptide Based Infection Therapeutics Market Analysis and Forecast, By Country, 2012-2022
11.1. GCC Countries Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       11.1.1. Revenue (US$ Mn) Comparison, By Drug 
       11.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
11.2. South Africa Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       11.2.1. Revenue (US$ Mn) Comparison, By Drug 
       11.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
11.3. Nigeria Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       11.3.1. Revenue (US$ Mn) Comparison, By Drug 
       11.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
11.4. Israel Peptide Based Infection Therapeutics Market Size and Forecast, 2012-2022
       11.4.1. Revenue (US$ Mn) Comparison, By Drug 
       11.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

12. Global Peptide Based Infection Therapeutics Market Competition Landscape and Company Profile
12.1. Company Share Analysis By Region
12.2. Vertex Pharmaceuticals Incorporated
       12.2.1. Company Overview
       12.2.2. Peptide Based Infection Therapeutics Market Drug list
       12.2.3. Peptide Based Infection Therapeutics Market Drug Sales Data and Key Financials
       12.2.4. Key Developments
       12.2.5. SWOT Analysis
12.3.Merck & Co., Inc.
       12.3.1. Company Overview
       12.3.2. Peptide Based Infection Therapeutics Market Drug list
       12.3.3. Peptide Based Infection Therapeutics Market Drug Sales Data and Key Financials
       12.3.4. Key Developments
       12.3.5. SWOT Analysis
12.4. Parchem Fine & Speciality Chemicals
       12.4.1. Company Overview
       12.4.2. Peptide Based Infection Therapeutics Market Drug list
       12.4.3. Peptide Based Infection Therapeutics Market Drug Sales Data and Key Financials
       12.4.4. Key Developments
       12.4.5. SWOT Analysis

13. Research Methodology

14. Secondary and Primary Sources

15. Assumptions and Acronyms

16. Disclaimer

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Peptide Based Infection Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022